文献速递骨质疏松与代谢性骨病

罗莫索单抗序贯地舒单抗治疗糖皮质激素性骨质疏松的随机临床试验

Efficacy of romosozumab followed by denosumab in glucocorticoid users; a randomized clinical trial.
PubMed 文献 · Osteoporos Int · 2026-06-16

36个月时腰椎骨密度中位变化百分比在ROMO-DMAb组最大(11.3%),高于地舒单抗组(9.4%)和双膦酸盐组(2.1%)。股骨颈和全髋骨密度变化在ROMO-DMAb与地舒单抗组间相似,且增幅远小于腰椎。

要点

  • ROMO-DMAb序贯治疗36个月腰椎BMD增幅最大(11.3%),优于地舒单抗(9.4%)和双膦酸盐(2.1%)。
  • 股骨颈和全髋BMD变化在ROMO-DMAb与地舒单抗组间相似,增幅远小于腰椎。
  • 所有组从第3个月起总I型前胶原N端前肽和抗酒石酸酸性磷酸酶5b血清水平均下降。

核心结论

  • 12个月罗莫索单抗序贯24个月地舒单抗治疗至36个月,腰椎骨密度增加幅度大于地舒单抗或双膦酸盐单药治疗。

研究设计与样本

  • 36个月期间每6个月测量腰椎、股骨颈和全髋骨密度。

主要发现

  • 患者中位年龄72.0岁(IQR 67.3-78.8),69.2%为女性,泼尼松龙剂量中位20.0 mg/天(IQR 15.0-50.0)。
  • 36个月时腰椎BMD相对基线中位变化百分比:ROMO-DMAb组11.3%(IQR 6.8-13.8),DMAb组9.4%(IQR 4.7-13.5),BP组2.1%(IQR -1.3-6.8)。
  • 股骨颈和全髋BMD变化在ROMO-DMAb与DMAb组间相似,且增幅远小于腰椎。
  • 所有组从第3个月起总I型前胶原N端前肽和抗酒石酸酸性磷酸酶5b血清水平均下降。

临床怎么用

  • 对于新开始糖皮质激素治疗且既往未用骨质疏松药物的风湿病患者,可考虑12个月罗莫索单抗序贯24个月地舒单抗以更显著提升腰椎骨密度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The efficacy of romosozumab (ROMO) in treating glucocorticoid-induced osteoporosis remains unclear. This randomized clinical trial demonstrated that in patients initiating glucocorticoid therapy, a treatment regimen of 12 months of ROMO followed by 24 months of denosumab (DMAb) was effective compared to either 36 months of DMAb or bisphosphonate monotherapy. PURPOSE: The efficacy of romosozumab (ROMO), an antibody against sclerostin-an inhibitor of Wnt signaling-in the treatment of glucocorticoid-induced osteoporosis remains uncertain, particularly regarding the sequential use of ROMO and denosumab (DMAb). This study aimed to compare the long-term efficacy of 12 months of ROMO followed by 24 months of DMAb (ROMO-DMAb) to 36 months of DMAb or bisphosphonates (BP) alone. METHODS: Patients with rheumatic diseases who had not previously received osteoporosis drugs and were newly treated with prednisolone ≥ 15 mg/day were randomly assigned to receive ROMO (ROMO-DMAb group), DMAb, or risedronate. Over a 36-month period, we measured bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip every 6 months. RESULTS: Thirty-nine patients (median [interquartile ranges] age 72.0 [67.3 - 78.8] years; 69.2% women; prednisolone dose 20.0 [15.0 - 50.0] mg/day) were enrolled. The median percent change in lumbar spine BMD from baseline at 36 months was greatest in the ROMO-DMAb group (ROMO-DMAb; 11.3 [6.8 - 13.8] %, DMAb; 9.4 [4.7 - 13.5] %, BP; 2.1 [-1.3 - 6.8] %). The changes in the femoral neck and total hip were similar between the ROMO-DMAb and DMAb groups, and the increases were much smaller than that in the lumbar spine. Serum levels of total type I procollagen-N-propeptide and tartrate-resistant acid phosphatase-5b decreased in all groups from month 3. CONCLUSION: Sequential treatment with ROMO followed by DMAb increased lumbar spine BMD more than DMAb or BP alone up to 36 months, demonstrating the efficacy of this treatment strategy.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kawazoe M, Masuoka S, Kaneko K, et al. Efficacy of romosozumab followed by denosumab in glucocorticoid users; a randomized clinical trial. Osteoporos Int. 2026. PMID: 42301302. doi:10.1007/s00198-026-08103-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。